Dergiler / Diagnostic and Interventional Radiology / 2020 / Cilt: 26 - Sayı: 1

Combination of Intraoperative Radiofrequency Ablation and Surgical Resection for Treatment of Cholangiocarcinoma: Feasibility and Long-term survival

Sayfa
45–52
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

This strategy provides acceptable local tumor control and overall survival.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:PURPOSE Most patients with intrahepatic cholangiocarcinoma (ICC) are not eligible for surgical resection due to advanced stage.
📊
Temel Bulgular & Veri:METHODS From 2009 to 2016, 20 consecutive patients (12 primary ICC, 8 recurrent ICC) underwent curative IORFA with hepatic resection for surgically unresectable ICC.
💡
Sonuç & Katkı:This strategy provides acceptable local tumor control and overall survival.
🔬Tür:Araştırma Makalesi
📍Kapsam:2009 Verileri
⚙️Değişkenler:Alan Parametreleri

Özet

PURPOSE Most patients with intrahepatic cholangiocarcinoma (ICC) are not eligible for surgical resection due to advanced stage. We aimed to evaluate the feasibility, local tumor control, and long-term survival of intraoperative radiofrequency ablation (IORFA) with surgical resection to treat unresectable intrahepatic cholangiocarcinoma (ICC). METHODS From 2009 to 2016, 20 consecutive patients (12 primary ICC, 8 recurrent ICC) underwent curative IORFA with hepatic resection for surgically unresectable ICC. Patients were not qualified to undergo surgical resection due to multiple lesions causing postoperative hepatic insufficiency and undesirable tumor locations for surgical resection or percutaneous RFA. Of the 51 treated tumors (mean, 2.6±0.9 tumors/patient), 24 were treated by IORFA and 27 were surgically removed. The technical success and effectiveness, overall survival, progression-free survival (PFS), and complications were assessed retrospectively. The overall survival and PFS rates were estimated by the Kaplan-Meier method. RESULTS The technical success and effectiveness of IORFA were 100%. The overall survival rates at 6 months, 1, 3, and 5 years were 95%, 79%, 27%, and 14%, respectively. The median overall survival time was 22.0±3.45 months. The PFS rates at 6 months, 1, 3, and 5 years were 70%, 33%, 13%, and 13%, respectively. The median PFS was 9.0±1.68 months. The prognosis was significantly worse for patients with recurrent ICC than for patients with primary ICC. One patient (5%) had major complications due to IORFA such as liver abscess and biliary stricture. CONCLUSION IORFA with surgical resection can be a feasible option for ICC cases that are not amenable to treatment with surgical resection alone. This strategy provides acceptable local tumor control and overall survival.

🔖

Bu Makaleye Atıf Yap

LEE, S. M., KO, H. K., SHIN, J. H., KIM, J. H., CHU, H. H. (2020). Combination of Intraoperative Radiofrequency Ablation and Surgical Resection for Treatment of Cholangiocarcinoma: Feasibility and Long-term survival. Diagnostic and Interventional Radiology, Cilt: 26 - Sayı: 1, 45–52. https://ajindex.com/articles/148837

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (14)

  1. Khan SA, Thomas HC, Davidson BR, Taylor-Robinson SD. Cholangiocarcinoma. Lancet 2005
  2. 1303–1314. [CrossRef] Aljiffry M, Walsh MJ, Molinari M. Advances in diagnosis, treatment and palliation of cholangiocarcinoma: 1990-2009. World J Gastroenterol 2009
  3. 4240–4262. [CrossRef] Park J, Kim MH, Kim KP, et al. Natural history and prognostic factors of advanced cholangiocarcinoma without surgery, chemotherapy, or radiotherapy: a large-scale observational study. Gut Liver 2009
  4. 298–305. [CrossRef] Burger I, Hong K, Schulick R, et al. Transcatheter arterial chemoembolization in unresectable cholangiocarcinoma: initial experience in a single institution. J Vasc Interv Radiol 2005
  5. 353–361. [CrossRef] Mazhar D, Stebbing J, Bower M. Chemotherapy for advanced cholangiocarcinoma: what is standard treatment? Future Oncol 2006
  6. 509–514. [CrossRef] Saxena A, Bester L, Chua TC, Chu FC, Morris DL. Yttrium-90 radiotherapy for unresectable intrahepatic cholangiocarcinoma: a preliminary assessment of this novel treatment option. Ann Surg Oncol 2010
  7. 484–491. [CrossRef] de Baere T, Deschamps F, Briggs P, et al. Hepatic malignancies: percutaneous radiofrequency ablation during percutaneous portal or hepatic vein occlusion. Radiology 2008
  8. 1056–1066. [CrossRef] Han K, Ko HK, Kim KW, et al. Radiofrequency ablation in the treatment of unresectable intrahepatic cholangiocarcinoma: systematic review and meta-analysis. J Vasc Interv Radiol 2015
  9. 943–948. [CrossRef] Stang A, Fischbach R, Teichmann W, Bokemeyer C, Braumann D. A systematic review on the clinical benefit and role of radiofrequency ablation as treatment of colorectal liver metastases. Eur J Cancer 2009
  10. 1748–1756. [CrossRef] Kim JH, Won HJ, Shin YM, Kim KA, Kim PN. Radiofrequency ablation for the treatment of primary intrahepatic cholangiocarcinoma. AJR Am J Roentgenol 2011
  11. W205–209. [CrossRef] Kim JH, Won HJ, Shin YM, et al. Radiofrequency ablation for recurrent intrahepatic cholangiocarcinoma after curative resection. Eur J Radiol 2011
  12. e221–225. [CrossRef] Tepel J, Hinz S, Klomp HJ, Kapischke M, Kremer B. Intraoperative radiofrequency ablation (RFA) for irresectable liver malignancies. Eur J Surg Oncol 2004
  13. 551–555. [CrossRef] Pawlik TM, Vauthey JN, Abdalla E, et al. Results of a single-center experience with resection and ablation for sarcoma metastatic to the liver. Arch Surg 2006
  14. 537–544. [CrossRef] Jones RL, McCall J, Adam A, et al. Radiofrequency ablation is a feasible ther